

Letter to the editor: 'Advances in biomarker discovery for peripartum cardiomyopathy: current status and future directions'

Jakob Triebel

To cite this article: Jakob Triebel (29 May 2026): Letter to the editor: 'Advances in biomarker discovery for peripartum cardiomyopathy: current status and future directions', Expert Review of Cardiovascular Therapy, DOI: [10.1080/14779072.2026.2682165](https://doi.org/10.1080/14779072.2026.2682165)

To link to this article: <https://doi.org/10.1080/14779072.2026.2682165>



Published online: 29 May 2026.



Submit your article to this journal [↗](#)



View related articles [↗](#)



View Crossmark data [↗](#)

LETTER TO THE EDITOR



Letter to the editor: 'Advances in biomarker discovery for peripartum cardiomyopathy: current status and future directions'

Jakob Triebel

Institute for Laboratory Medicine and Infectious Diseases, Nuremberg General Hospital & Paracelsus Medical University, Nuremberg, Germany

ARTICLE HISTORY Received 19 December 2025; Accepted 27 May 2026

KEYWORDS Prolactin; vasoinhibin; ELISA; antibody; heart failure

The statement by Pretorius et al. that vasoinhibin (16-kDa PRL) has not yet been successfully detected in human serum samples is inaccurate, as our group has previously demonstrated reliable detection. Monoclonal antibodies against vasoinhibin have been developed and reported [1,2], are commercially available, and were successfully employed in a sandwich-type ELISA that quantifies vasoinhibin concentrations in human serum with a quantification limit of 3 ng/ml [3]. We trust that this clarification will contribute to a more accurate representation of the current state of vasoinhibin detection in peripartum cardiomyopathy research.

Funding

This paper was not funded.

Declaration of interest

The anti-vasoinhibin monoclonal antibodies are covered by an international patent application filed by J Triebel (PCT/EP2024/073698).

Commercial production and distribution have been licensed to Davids Biotechnologie GmbH, Regensburg, Germany.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

References

1. Muller N, Robles JP, Zamora M, et al. Development of vasoinhibin-specific monoclonal antibodies. *Front Endocrinol (Lausanne)*. 2021;12:645085. doi: [10.3389/fendo.2021.645085](https://doi.org/10.3389/fendo.2021.645085)
2. Triebel J, Bertsch T. Sequencing report of a monoclonal vasoinhibin antibody. *Commun Prolactin Res*. 2025. doi: [10.63701/cpr.3](https://doi.org/10.63701/cpr.3)
3. Zamora M, Harris D, Davies N, et al. Immunometric and functional measurement of endogenous vasoinhibin in human sera. *Front Endocrinol (Lausanne)*. 2024;15:1345996. doi: [10.3389/fendo.2024.1345996](https://doi.org/10.3389/fendo.2024.1345996)